Humana Inc. (NYSE:HUM) Position Increased by Massmutual Trust Co. FSB ADV

Massmutual Trust Co. FSB ADV lifted its holdings in shares of Humana Inc. (NYSE:HUM) by 124.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 299 shares of the insurance provider’s stock after buying an additional 166 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Humana were worth $112,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. First Hawaiian Bank increased its position in Humana by 181.7% during the second quarter. First Hawaiian Bank now owns 7,906 shares of the insurance provider’s stock worth $2,954,000 after buying an additional 5,099 shares during the last quarter. GAMMA Investing LLC grew its position in Humana by 127.2% in the second quarter. GAMMA Investing LLC now owns 759 shares of the insurance provider’s stock valued at $284,000 after acquiring an additional 425 shares during the period. Transcend Capital Advisors LLC acquired a new position in Humana in the second quarter valued at about $433,000. Kathmere Capital Management LLC acquired a new stake in shares of Humana in the second quarter valued at $170,000. Finally, Clear Rock Advisors LLC lifted its holdings in Humana by 4.0% during the 1st quarter. Clear Rock Advisors LLC now owns 5,131 shares of the insurance provider’s stock worth $1,779,000 after buying an additional 199 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HUM has been the topic of several analyst reports. Royal Bank of Canada dropped their target price on Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Bank of America boosted their price objective on shares of Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a research report on Monday, May 20th. TD Cowen raised their price objective on shares of Humana from $396.00 to $407.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Baird R W raised shares of Humana to a “hold” rating in a research report on Thursday, May 30th. Finally, Robert W. Baird began coverage on shares of Humana in a research report on Thursday, May 30th. They set a “neutral” rating and a $374.00 price objective for the company. Fourteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Humana presently has an average rating of “Hold” and an average target price of $403.55.

Humana Stock Performance

Shares of HUM stock traded down $1.04 during trading on Tuesday, reaching $355.25. The company had a trading volume of 876,182 shares, compared to its average volume of 1,739,707. Humana Inc. has a one year low of $298.61 and a one year high of $530.54. The firm’s 50 day simple moving average is $368.04 and its two-hundred day simple moving average is $347.41. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.67. The company has a market capitalization of $42.77 billion, a PE ratio of 22.10, a PEG ratio of 2.09 and a beta of 0.51.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. Humana’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the business earned $8.94 earnings per share. Sell-side analysts forecast that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.